MedTrace Logo

Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

NCT05153395 · Status: SUSPENDED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-12-19

No results posted yet for this study

Summary

The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.

Conditions

Interventions

OTHER

Carbon dioxide breathing

Hypercapnic (5% carbon dioxide) air will be administered before and after intra-nasal insulin exposure.

OTHER

Neurovascular Coupling

Participants will be asked to repeatedly open and close their eyes. With eyes open, participants will focus on a visual image. This will be done before and after intra-nasal insulin exposure.

DRUG

Human insulin

Participants will be administered human insulin (160 IU) as a bolus using an intra-nasal device.

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Jacqueline K Limberg, Ph.D. · University of Missouri-Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153395 on ClinicalTrials.gov